Simulating androgen receptor selection in designer yeast

Matsumoto, 2013, The androgen receptor in health and disease, Annu Rev Physiol, 75, 201, 10.1146/annurev-physiol-030212-183656 Handelsman, 2018, Circulating testosterone as the hormonal basis of sex differences in athletic performance, Endocr Rev, 39, 803, 10.1210/er.2018-00020 Swerdloff, 2017, Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels, Endocr Rev, 38, 220, 10.1210/er.2016-1067 Brown, 1988, Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome, Proc Natl Acad Sci U S A, 85, 8151, 10.1073/pnas.85.21.8151 Asahiro, 2000 Lim, 2021, Gene therapy with AR isoform 2 rescues spinal and bulbar muscular atrophy phenotype by modulating AR transcriptional activity, Sci Adv, 7, 1, 10.1126/sciadv.abi6896 Badders, 2018, Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy, Nat Med, 24, 427, 10.1038/nm.4500 Morova, 2020, Androgen receptor-binding sites are highly mutated in prostate cancer, Nat Commun, 11, 10.1038/s41467-020-14644-y Ary -e Llen Aplin, 1995, 332 Lallous, 2016, Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients, Genome Biol, 17, 10.1186/s13059-015-0864-1 Watson, 2015, Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer, Nat Rev Cancer, 15, 701, 10.1038/nrc4016 Yuan, 2014, Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis, Oncogene, 33, 2815, 10.1038/onc.2013.235 Collier, 2012, Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review, Am J Clin Oncol: Cancer Clin Trials, 35, 504, 10.1097/COC.0b013e318201a406 Chang, 2011, Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer, Proc Natl Acad Sci U S A, 108, 13728, 10.1073/pnas.1107898108 Feldman, 2001, The development of androgen-independent prostate cancer, Nat Rev Cancer, 1, 34, 10.1038/35094009 Ferraldeschi, 2014, Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects, Oncogene, 34, 1745, 10.1038/onc.2014.115 Tran, 2009, Development of a second-generation antiandrogen for treatment of advanced prostate cancer, Science, 324 Rathkopf, 2013, Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer, J Clin Oncol, 31, 3525, 10.1200/JCO.2013.50.1684 Wirth, 2007, Antiandrogens in the treatment of prostate cancer, Eur Urol, 51, 306, 10.1016/j.eururo.2006.08.043 Tan, 2015, Androgen receptor: structure, role in prostate cancer and drug discovery, Acta Pharmacol Sin, 36, 3, 10.1038/aps.2014.18 O'Mahony, 2008, Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer, Mol Cancer Res, 6, 1691, 10.1158/1541-7786.MCR-08-0273 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 10.1016/j.cell.2015.05.001 Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur Urol, 63, 10.1016/j.eururo.2012.08.053 Azad, 2015, Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer, Clin Cancer Res, 21, 2315, 10.1158/1078-0432.CCR-14-2666 Gottlieb, 2012, The androgen receptor gene mutations database: 2012 update, Hum Mutat, 33, 887, 10.1002/humu.22046 Xie, 2017, “Perfect” designer chromosome v and behavior of a ring derivative, Science, 355 Wu, 2017, vol. 355 Jia, 2018, Precise control of SCRaMbLE in synthetic haploid and diploid yeast, Nat Commun, 9, 10.1038/s41467-018-03084-4 Xie, 2017, Design and chemical synthesis of eukaryotic chromosomes, Chem Soc Rev, 46, 7191, 10.1039/C7CS00208D Xie, 2021, Debugging: putting the synthetic yeast chromosome to work, Chem Sci, 12, 5381, 10.1039/D0SC06924H Chen, 2021, An artificial chromosome for data storage, Natl Sci Rev, 8, 1, 10.1093/nsr/nwab028 Zhou, 2021, Directed genome evolution driven by structural rearrangement techniques, Chem Soc Rev, 50, 12788, 10.1039/D1CS00722J Harms, 2014, Historical contingency and its biophysical basis in glucocorticoid receptor evolution, Nature, 512, 203, 10.1038/nature13410 Chockalingam, 2005, Directed evolution of specific receptor-ligand pairs for use in the creation of gene switches, AIChE Annual Meeting, Conference Proceedings, 102, 9272 Chen, 2004, Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity, J Biol Chem, 279, 33855, 10.1074/jbc.M402118200 Rahman, 2004, Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications, Clin Cancer Res, 10, 10.1158/1078-0432.CCR-0746-3 Kohalmi, 1997 Liu, 1999, Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin, Proc Natl Acad Sci U S A, 96 Spencer, 1997, Steroid receptor coactivator-1 is a histone acetyltransferase, Nature, 389, 10.1038/38304 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 Blackledgea, 1997, vol. 31 Furr, 1996, vol. 29 Giuliani, 1980, Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy - 5-year follow-up, Eur Urol, 6, 10.1159/000473313 Hinkel, 1996, Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients, Eur Urol, 30, 10.1159/000474216 Hara, 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome, Cancer Res, 63, 149 Bohl, 2005 Yoshida, 2005, Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient, Cancer Res, 65, 9611, 10.1158/0008-5472.CAN-05-0817 Veldscholte, 1994, Studies on the human prostatic cancer cell line LNCaP, J Steroid Biochem Mol Biol, 49, 341, 10.1016/0960-0760(94)90277-1 Sun, 2006, Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival, Oncogene, 25, 10.1038/sj.onc.1209424 Chen, 2015, Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors, Clin Cancer Res, 21, 10.1158/1078-0432.CCR-14-1220 Balbas, 2013, Overcoming mutation-based resistance to antiandrogens with rational drug design, Elife, 2, 1, 10.7554/eLife.00499 Korpal, 2013, An F876l mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide), Cancer Discov, 3, 1030, 10.1158/2159-8290.CD-13-0142 Veldscholte, 1990, A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens, Biochem Biophys Res Commun, 173, 534, 10.1016/S0006-291X(05)80067-1 Fizazi, 2020, Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide, N Engl J Med, 383, 10.1056/NEJMoa2001342 Borgmann, 2018, Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201), Eur Urol, 73, 10.1016/j.eururo.2017.08.012 Lallous, 2021, Evaluation of darolutamide (Odm201) efficiency on androgen receptor mutants reported to date in prostate cancer patients, Cancers, 13, 10.3390/cancers13122939 Schaufele, 2005, The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions, Proc Natl Acad Sci U S A, 102, 10.1073/pnas.0408819102 He, 1991, A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicularfeminized mouse, Nucleic Acids Res, 19, 10.1093/nar/19.9.2373 Miyamoto, 1998, Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells, Proc Natl Acad Sci U S A, 95, 10.1073/pnas.95.13.7379 James, 2002, A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity, Mol Endocrinol, 16, 2692, 10.1210/me.2001-0281 Evans, 1988 Joseph, 2013, A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509, Cancer Discov, 3, 1020, 10.1158/2159-8290.CD-13-0226 Snow, 2020, Deep learning modeling of androgen receptor responses to prostate cancer therapies, Int J Mol Sci, 21, 10.3390/ijms21165847 Shi, 2002, Functional analysis of 44 mutant androgen receptors from human prostate cancer, Cancer Res, 62, 1496 Heinlein, 2002 Brooke, 2008, Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression, Oncogene, 27, 2941, 10.1038/sj.onc.1210955 Agoulnik, 2005, Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression, Cancer Res, 65, 7959, 10.1158/0008-5472.CAN-04-3541 Gregory, 2001, A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy, Cancer Res, 61